Recently, it was proposed that neuropeptide Y (NPY) and peptide YY (PYY) could act as endogenous ligands for u binding sites, as both NPY and PYY competed with high affinity (nanomolar) for 3H-( +)SKF 10,047 binding sites in rat brain membrane homogenates (Roman et al., 1989 The existence of sigma (0) receptor binding sites in the brain has generated much interest over the past few years likely because of their possible involvement in psychosis-related behaviors (for recent reviews, see Deutsch et al., 1988; Junien and Leonard, 1989; Snyder and Largent, 1989; Chavkin, 1990; Musacchio, 1990; Walker et al., 1990; Ferris et al., 199 1; Itzhak and Stein, 199 la; Su, 199 1) . This assumption is mostly based on the fact that high densities of (r binding sites are found in various limbic structures, including the hippocampus (Gundlath et al., 1986; Contreras et al., 1987b; McLean and Weber, 1988) , and to the high affinity of some neuroleptics (e.g., haloperidol and remoxipride, but not sulpiride) for g sites (Su, 1982, 199 1; Tam and Cook, 1984; Taylor and Dekleva, 1987) . This suggested the possible development of a new class of u-related antipsychotic drugs devoid of dopaminergic activity (Su, 1986; Taylor and Dekleva, 1987; Snyder and Largent, 1989) . Additional support for this hypothesis came from observations suggesting that certain g drugs such as N-allylnormetazocine (NANM or SKF 10,047) induced hallucinations in man (Keats and Telford, 1964 ) and delirium in the chronic spinal dog (Martin et al., 1976; Vaupel, 1983) although the genuine u nature of these effects remains to be fully established (Quirion et al., 1987; Walker et al., 1990) .
The abundance and discrete distribution of u sites in the mammalian brain may also reveal the possible existence of endogenous u-related ligands. Early on, few groups (Quirion et al., 1984; Su et al., 1986; Contreras et al., 1987a; Su and Vaupel, 1988; Zhang et al., 1988; Chavkin, 1991, 1992) reported on the possible isolation of such molecules, although their purification to homogeneity still remains to be accomplished. Thus, the report by Roman et al. (1989) suggesting that peptides of the pancreatic polypeptide family, namely, neuropeptide Y (NPY) and polypeptide YY (PYY), were able to compete with high affinities for in vitro 3H-(+)SKF 10,047/u binding sites generated tremendous interests. However, it has been difficult to replicate these findings using well-established in vitro membrane binding assays (Quirion et al., 199 1; Tam and Mitchell, 199 1) .
On the other hand, evidence has recently accumulated supporting the existence of interactions between NPY and u-related systems, in vivo. For example, Monnet et al. (1990a Monnet et al. ( ,b, 1992a have shown that both NPY and u agonists, in a haloperidolsensitive manner, are able to potentiate N-methyl-D-aspartate (NMDA)-induced firing in the pyramidal CA3 subfield of the hippocampal formation (but see McQuiston and Colmers, 199 I ; Connick et al., 1992) . Additionally, NPY and a selective u ligand, JO 1784, can decrease intestinal transport apparently via haloperidol-sensitive c receptors (Riviere et al., 1990) . Moreover, it appears that NPY and homologs, as well as various u ligands, are able to potentiate NMDA-induced 3H-noradrenaline release in rat hippocampal slices (Monnet et al., 199 1; Ro-man et al., 199 1). Accordingly, we decided to investigate further possible interactions between NPY-related peptides and g receptor sites in the mouse hippocampus using an in vivo binding approach; the hippocampal formation was chosen as this region is most enriched with both g- (Gundlach et al., 1986; Contreras et al., 1987b; McLean and Weber, 1988; Weissman et al., 1988 Weissman et al., , 1990 and NPY (Martel et al., 1986 (Martel et al., , 1990a Lynch et al., 1989; Dumont et al., 1990 Dumont et al., , 1992 Dumont et al., ,1993 Jouveinal, Fresnes, France. All NPY-related peptides as well as neurotensin and vasoactive intestinal polypeptide (VIP) were synthesized in our laboratories as described earlier (St.-Pierre et al., 1981; Martel et al., 1990b) . Adrenalin, haloperidol, trizma base (Tris), NaCl, and polyethyleneimine (PEI) were purchased from Sigma Chemicals ( Animals were killed by dislocation at t = 60 min. Brains were then rapidly removed and hippocampi were dissected on ice and immediately homogenized in 1 ml of ice-cold buffer (Tris-HC15 mtq pH 7.4 at 4°C) using a Teflon/glass Potter-Elvehjem probes (12 strokes). Immediately thereafter, 1 ml of ice-cold Tris-HCl buffer was added to this homogenate before filtration of 1.5 ml of this preparation through three GF/ B glass filters (pretreated for at least 24 hr in buffer containing 0.05% PEI) under vacuum using a 12-hole Millipore CAT apparatus. Filters were then washed twice with 5 ml of ice-cold incubation buffer and then placed in vials containing 5 ml of Ecolite TM+ scintillation cocktail. Radioactivity was determined using a Beckman LS1800 counter with 40% efficiency. The remaining 0.5 ml of the homogenate was kept for protein determination (Lowry et al., 1951) . Statistical analyses were performed using the Student's t test, p < 0.05 being considered statistically significant.
Results
In preliminary experiments we failed to obtain evidence for in vitro interactions between NPY, PYY, and 3H-(+)SKF 10,047/ a sites as the two peptides, in concentrations ranging from lO-1' to 1 O-6 M, did not compete for in vitro 3H-( +)SKF 10,047 binding in mouse brain membrane preparations. These findings confirmed data obtained earlier in the rat brain (Quirion et al., 199 1; Tam and Mitchell, 1991) . presence of haloperidol(2 mg/kg, i.p.) residual 3H-( +)SKF 10,047 hippocampal binding accounted for only 1.48 fmol/mg of protein, revealing that approximately 90% (13.52 fmol/mg protein) of total labeling was sensitive to the prototypical g ligand (Fig.  1) . The NMDA/phencyclidine (PCP) receptor ligand MK-801 did not inhibit the specific )H-(+)SKF 10,047 labeling in the mouse hippocampal formation at intraperitoneal doses of 0.05, 0.1, 0.2, and 0.5 mg/kg (n = 26; data not shown).
Competition by NPY-related peptides
As shown in Figure 3 , NPY, NPY,_,,, Leu31,Pro34-NPY (a purported Y, agonist; Fuhlendorff et al., 1990) , and PYY were able to displace approximately one-third of specific in vivo )H-( +)SKF 10,047 labeling in the mouse hippocampus. The fragment NPY ,% 36 (a Y, agonist; Wahlestedt et al., 1986 ) and the analog desamido-NPY (NPY-OH) were inactive. As shown in Figure 2 , various doses ofNPY (300,600, 1000, 1500, and 3000 pmol, i.c.v.) demonstrated that this peptide inhibited the in vivo hippocampal labeling of 3H-(+)SKF 10,047 in a dose-related manner. The minimal effective dose appears to be in the range of 600 pmol while a maximal effect was observed at 1500 pmol, a higher dose of NPY (3000 pmol) failing to produce a greater effect (Fig. 2) .
The respective potency of various NPY-related peptides to inhibit in vivo 3H-(+)SKF 10,047 labeling in the mouse hippocampus is shown in Figure 3 . At doses of 1500 and 3000 pmol, the homolog PYY most potently inhibited specific 3H-(+)SKF 10,047 labeling, its effects being apparently even greater than that of NPY. In contrast, NPY-OH failed to inhibit 3H-(+)SKF 10,047 labeling (Fig. 3A) , as expected for this biologically inactive analog (Wahlestedt et al., 1986) .
The fragment NPY,_,, was able to mimic the effect of the full NPY molecule on 'H-(+)SKF 10,047 labeling (Fig. 3B) . However, a shorter C-terminal fragment, NPY,,_,,, a purported Y, agonist (Wahlestedt et al., 1986 ), failed to alter )H-( +)SKF 10,047 labeling at 1500 pmol (Fig. 3B) . On the other hand, the Y, agonist L~u~',P~~~~-NPY, was the most potent competitor of in vivo 3H-(+)SKF 10,047 labeling tested in this study, with a profile similar to that of NPY, namely, a dose of 1500 pmol inducing a greater effect than that of 3000 pmol (Figs. 2, 3B) . 10,047 labeling (total n = 5 1) with a minimally effective dose in the range of 600 pmol (n = 23); a lower dose (300 pmol; n = 25) inhibited binding to a nonsignificant extent; 1000 omol (n = 23) uroduced a areater inhibition than that of 600 umol. while-maximal effectiveness was observed at 1500 pmol (n = 23); with 3000 pmol (n = 11) being somewhat less effective. *, p < 0.05; **, p < 0.005.
-.. As a means to assess the specificity of the effect of NPY and related analogs for in vivo 3H-(+)SKF 10,047 labeling, we investigated next the effects of two other classes ofpeptides, namely, neurotensin (1500 pmol) and VIP (1500 pmol), and of the well-known vasoconstrictor/neurotransmitter adrenalin (1500 and 3000 pmol). These three molecules failed to alter in vivo JH-( +)SKF 10,047 labeling in the mouse hippocampus at doses tested here (Fig. 4) .
Discussion
The present study demonstrates that (1) NPY and its homolog PYY dose-dependently inhibited the in vivo binding of the prototypical (r ligand 'H-( +)SKF 10,047 in the mouse hippocampal formation; (2) a similar effect is also seen with a Y, (Leu3L,Pro34-NPY) but not a Y, (NPY ,*-)J receptor agonist, suggesting receptor subtype specificity; (3) a biologically inactive NPY analog, NPY-OH, failed to alter in vivo 3H-(+)SKF 10,047 labeling; and (4) other biologically active polypeptides such as neurotensin and VIP, which are known to induce various cerebrovascular and neuronal effects (Rioux et al., 198 1; Wilson et al., 1981) and adrenalin failed to modulate in vivo 3H-( +)SKF 10,047 labeling, demonstrating the specificity of the interactions between certain NPY-related peptides and in vivo 3H-(+)SKF 10,047 binding in the mouse hippocampus.
The hippocampal labeling observed following an intravenous injection of 3H-( +)SKF 10,047 is very likely representing binding to G sites that are most abundant in this region (Largent et al., 1986; Contreras et al., 1987b; Weissman et al., 1990) . While (+)SKF 10,047 can bind with relatively high affinities to both PCP and u sites (Su, 1982; Largent et al., 1986; Quirion et al., 1987; McCann et al., 1989) only the d component is sensitive to haloperidol (Su, 1982; Tam and Cook, 1984) . Moreover, four different doses (0.05, 0.1, 0.2, and 0.5 mg/kg, i.p.; n = 26) of the high-affinity NMDA/PCP receptor ligand MK-80 1 (Loo et al., 1987) did not reduce the specific in vivo 3H-( +)SKF 10,047 labeling in the mouse hippocampus. Thus, the high sensitivity (X 100 pmol) Figure 3 . A, Comparative potencies of NPY, PYY, and NPY-OH to inhibit in vivo 'H-(+)SKF 10,047 labeling (total n = 51) in the mouse hippocampal formation. PW at 1500 pmol (n = 13) and 3000 pmol (n = 8) was slightly more potent than NPY at 1500 pmol (n = 23) to inhibit labeling, while NPY-OH at 1500 pmol (n = 7) and 3000 pmol (n = 13) failed to produce any significant effect. *, p < 0.005. B, Comparative potencies of NPY ,-)6, C-terminal fragments (NPY,,, and NPY ,3. J, and the analog f,et~~',Pro~~-NPY (ZJ) to inhibit in vivo 3H-(+)SKF 10,047 labeling (total n = 51) in the mouse hippocampal formation. NPY,-3, at 1500 pmol (n = 20) and 3000 pmol (n = 10) significantly inhibited )H-(+)SKF 10,047 binding albeit to a lower extent than the full peptide, at 1500 pmol (n = 23). A prototypical Y, fragment, NPY,, 1A (1500 omol. n = 14). failed to exert anv effect on )H-(+)SKF 10.047 labeling,-while the Y I'agonist Leu )I Pro);-NPY potent& dompeted for labeling at 1500 pmol (n = 14) and ;OOO pmol (n = 7). *, p < 0.05; **, p < 0.005. of in vivo hippocampal 3H-(+)SKF 10,047 labeling to haloperidol, together with the ineffectiveness of MK-80 1 to inhibit the specific 3H-(+)SKF 10,047 labeling in the mouse hippocampus in vivo, confirms the c nature of the related sites. Our results also extend previously reported in vivo 3H-(+)SKF 10,047/urelated binding data (Ferris et al., 1988; Tam et al., 1988; Weissman et al., 1990) . However, it is unclear if, under the present assay conditions, in vivo 3H-( +)SKF 10,047 labeling represents binding to more than one subtype of (T site. Recently, evidence has been obtained to support the existence of at least two classes (al and ~2) of u sites (Hellewell and Bowen, 1990 ; Itzhak and Stein, 1991a,b; Itzhak et al., 1991; Su et al., 1991; Quirion et al., 1992; Vilner and Bowen, 1992) . These two putative subtypes demonstrate similar affinity for haloperidol, while (+)SKF 10,047 apparently preferentially labels the ~rl sites (Hellewell and Bowen., 1990; Itzhak and Stein, 1991 b; Itzhak et al., 1991; Su et al., 199 1; Quirion et al., 1992; Vilner and Bowen, 1992) although it can also possibly bind to the a2 site at concentrations comparable to that used in the present study (5 WCi, i.v.) . Additional experiments using other a-related radioligands such as 3H-(+)pentazocine (al) and )H-DTG (in presence of a saturating concentration of dextrallorphan) for u2 sites (DiPaolo et al., 199 1; Bowen et al., 1992) will be required to clarify this issue. Already, in a series of preliminary experiments, we attempted to investigate the in vivo labeling of the mouse hippocampus following intravenous injections of either )H-DTG or )H-(+)pentazocine. However, in contrast to 3H-( +)SKP 10,047, the amounts of radioactivity recovered in the hippocampal formation using either probe were too low to permit adequate pharmacological characterization (1 SO-500 dpm per 5 FCi). Moreover, in vivo 3H-DTG labeling was apparently mostly restricted to ventricular epithelia as revealed by in vivo autoradiography (P. Bouchard, Y. Dumont, A. Foumier, S. St.-Pierre, and R. Quirion, unpublished observations). Thus, it appears that other radioligands will have to be developed in order to investigate adequately the in vivo binding profiles of ul and u2 sites in the mouse brain.
The extent of the competition seen between 'H-( +)SKF 10,047 and NPY-related peptides following their respective in vivo injections also supports the possible labeling by the radioligand of two classes of u site. While haloperidol competed for up to 90% of 3H-( +)SKF 10,047 labeling in the mouse hippocampus, intracerebroventricular injections of NPY and its homologs inhibited approximately one-third of the labeling, suggesting that 3H-( +)SKF 10,047 could interact with subtypes of u-sites, only one being accessible to NPY and related peptides.
The precise nature of in vivo interactions between 'H-( +)SKF 10,047 labeling and NPY remains speculative. It clearly displays specificity as two other families of well-known peptides, neurotensin and VIP, failed to alter in vivo 'H-( +)SKF 10,047 binding under our assay conditions. Similarly, the effects of NPYrelated peptides are unlikely to be related only to changes in cerebral blood flow as adrenalin, a potent constrictor of the cerebral vasculature, as well as neurotensin and VIP, two peptides with potent cerebrovascular activities (Rioux et al., 198 1; Wilson et al., 198 l) , failed to modify in vivo )H-(+)SKF 10,047 labeling of the mouse hippocampus.
We (Quirion et al., 199 1) and others (Tam and Mitchell, 199 1) were unable to obtain clear evidence for the existence of in vitro receptor binding interactions between a variety of U-and NPYrelated molecules. Interestingly, various peptidase inhibitors are generally used in in vitro binding assays to insure the integrity of NPY peptides used either as radioligands and/or competitors (Lynch et al., 1989; Mattel et al., 1990a,b; Quirion et al., 1991) . Could it be that an endogenously generated NPY metabolite is able to act as a u ligand in vivo? While clear evidence is currently lacking to support this hypothesis, Contreras et al. (1987a) proposed the existence of endogenous u ligands of peptidergic nature. It is thus of interest that only certain NPY-related peptides were able to modulate the in vivo labeling of 3H-(+)SKF 10,047 in the mouse hippocampus. Both NPY-OH and the relatively selective Y, agonist NPY ,3.)6 (Wahlestedt et al., 1986) (X 100 pmol)
F&we 4. Comparative effects of NPY (n = 23), neurotensin (NT; 1500 pmol, n = 9), VIP (1500 pmol, n = 17), and the catecholamine adrenalin (AAd: 1500 nmol. n = 7: 3000 nmol. n = 11) on in viva ,H-(+)SKF 10.047 labeling (total n = 51) in the m&se hinpocampal formation. At'this concentration, it is evident that only NPY significantly interacted with in vivo 3H-(+)SKF 10,047 labeling. *, p < 0.005.
Leu31,Pro34-NPY (Fuhlendorf et al., 1990) behaved as potent competitors. Taken together, these data may suggest that if a metabolite(s) of NPY is responsible for the inhibition of 3H-(+)SKF 10,047/u labeling, it could be an N-terminal fragment likely containing amino acid residue located between positions 2 and 13. Alternatively, it could be that NPY and some of its related peptides can induce the release of a yet to be characterized endogenous u ligand that could then inhibit the in vivo binding of 3H-(+)SKF 10,047. Recent data by Chavkin (1991, 1992) are especially interesting in that regard as they provide evidence for the existence of endogenous u ligands in the hippocampus. It is also possible that NPY-related peptides, by modulating signal transduction activity, could alter in vivo 3H-(+)SKF 10,047/u labeling. These various possibilities are currently under investigation. The ligand selectivity profile observed here for NPY and its homologs is most reminiscent of a Y,-like profile (Wahlestedt et al., 1986 (Wahlestedt et al., , 1990 Fuhlendorff et al., 1990; Quirion et al., 1990; Dumont et al., 1992) on the basis of the potent activity of the Y, analog Leu31,Pro34-NPY and the ineffectiveness of NPY,,_,,, a Y, agonist (Wahlestedt et al., 1986) to modulate hippocampal in vivo 'H-(+)SKF 10,047 labeling. The high potency of PYY in this assay would also exclude an interaction with the newly characterized Y, receptor subtype as PYY was reported to be inactive on this receptor class (Balasubramaniam et al., 1990; Grundemar et al., 1991; Wahlestedt et al., 1992) . While it is certainly too early to claim the existence of possible structural homologies between NPY and u receptor classes, the pattern of in vivo interactions observed in the present study and those of others (Monnet et al., 1990a,b) raises interesting possibilities as the various NPY receptor subtypes (Rimland et al., 199 1; Herzog et al., 1992; Larhammar et al., 1992) and likely the al site (Itzhak and Stein, 199 1 b; Itzak et al., 199 1; Quirion et al., 1992) could all belong to the G-protein<oupled rhodopsin receptor superfamily.
In summary, the present study revealed the existence of in vivo interactions between certain NPY-related peptides and 3H-(+)SKF 10,047/u labeling in the mouse hippocampus. Further studies are currently in progress to determine the mechanism(s) responsible for these interactions and the possible functional significance of these findings.
